Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing
neuroplasticity. In human patients, we quantified gray matter microstructural changes on a …

Background A significant proportion of adults with major depressive disorder (MDD) do not
respond to treatments which are currently used in clinical practice such as first-generation …

A high proportion of depressed patients fail to respond to antidepressant drug treatment.
Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of …

Background Depression, one of the most common mental illnesses and mood disorder
syndromes, can seriously harm physical and mental health. As the pathophysiology of …

Psychedelic medicine is an emerging field that examines entheogens, psychoactive
substances that produce non-ordinary states of consciousness (NOSC). 3, 4 …

What changes in brain function cause the debilitating symptoms of depression? Can we use
the answers to this question to invent more effective, faster acting antidepressant drug …

Ketamine, functioning as a channel blocker of the excitatory glutamate-gated N-methyl-d-
aspartate (NMDA) receptors, displays compelling fast-acting and sustained antidepressant …

Patients with cancer are at greater risk of developing depression in comparison to the
general population and this is associated with serious adverse effects, such as poorer …

Free d-amino acids (d-AAs) are emerging as a novel and important class of signaling
molecules in many organs, including the brain and endocrine systems. There has been …

Peripheral nerve injury (PNI) is a complex disease that often appears in young adults. It is
characterized by a high incidence, limited treatment options, and poor clinical outcomes …